Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Genetic and biological hallmarks of colorectal cancer
Colorectal cancer has served as a genetic and biological paradigm for the evolution of solid
tumors, and these insights have illuminated early detection, risk stratification, prevention …
tumors, and these insights have illuminated early detection, risk stratification, prevention …
Adjuvant therapy for stage II colon cancer: ASCO guideline update
NN Baxter, EB Kennedy, E Bergsland… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE To develop recommendations for adjuvant therapy for patients with resected
stage II colon cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
stage II colon cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …
Biomarker-guided therapy for colorectal cancer: strength in complexity
A Sveen, S Kopetz, RA Lothe - Nature Reviews Clinical Oncology, 2020 - nature.com
The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
[HTML][HTML] Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant …
PURPOSE: In patients with stage III colon cancer (CC) whose tumors demonstrate
microsatellite instability (MSI), the efficacy of adjuvant fluoropyrimidine (FP) with or without …
microsatellite instability (MSI), the efficacy of adjuvant fluoropyrimidine (FP) with or without …
[HTML][HTML] Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in …
R Dienstmann, G Villacampa, A Sveen, MJ Mason… - Annals of oncology, 2019 - Elsevier
Background It remains unknown to what extent consensus molecular subtype (CMS) groups
and immune-stromal infiltration patterns improve our ability to predict outcomes over tumor …
and immune-stromal infiltration patterns improve our ability to predict outcomes over tumor …
[HTML][HTML] Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives
F Battaglin, M Naseem, HJ Lenz… - Clinical advances in …, 2018 - ncbi.nlm.nih.gov
Microsatellite instability (MSI) is a key biomarker in colorectal cancer (CRC), with crucial
diagnostic, prognostic, and predictive implications. Testing for mismatch repair deficiency …
diagnostic, prognostic, and predictive implications. Testing for mismatch repair deficiency …
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
E Domingo, L Freeman-Mills, E Rayner… - The lancet …, 2016 - thelancet.com
Background Precision cancer medicine depends on defining distinct tumour subgroups
using biomarkers that may occur at very modest frequencies. One such subgroup comprises …
using biomarkers that may occur at very modest frequencies. One such subgroup comprises …
Molecular targeted therapy of BRAF-mutant colorectal cancer
M Ducreux, A Chamseddine… - … in medical oncology, 2019 - journals.sagepub.com
Over the past two decades, the molecular characterization of metastatic colorectal cancer
(mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As …
(mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As …